Press Releases

Date	Title	View
10/10/18	Summary Toggle Horizon Pharma plc to Release Third-Quarter 2018 Financial Results and Host Webcast on Nov. 7, 2018	PDF Version
10/04/18	Summary Toggle Horizon Pharma plc Announces Presentation of Data From 48 Week Off-Therapy Follow-Up to the Phase 2 Trial of Teprotumumab	PDF Version
09/27/18	Summary Toggle The North American Pediatric Renal Trials and Collaborative Studies and Horizon Pharma plc Announce New Long-Term Cystinosis Registry	PDF Version
09/27/18	Summary Toggle Horizon Pharma plc Initiates Clinical Trial to Evaluate KRYSTEXXA® (pegloticase injection) with Methotrexate to Enhance Response Rates for People Living with Uncontrolled Gout	PDF Version
09/25/18	Summary Toggle Horizon Pharma plc to Present 48-Week Follow-Up Analysis of the Teprotumumab Phase 2 Trial at the Annual Meeting of the American Thyroid Association	PDF Version
09/04/18	Summary Toggle Horizon Pharma plc to Participate in the Morgan Stanley 16th Annual Global Healthcare Conference	PDF Version
09/04/18	Summary Toggle Horizon Pharma plc Completes Enrollment of Confirmatory Phase 3 Trial of Teprotumumab Ahead of Schedule	PDF Version
08/08/18	Summary Toggle Horizon Pharma plc Reports Record Quarterly Net Sales for Orphan and Rheumatology Segment; Increases Full-Year 2018 Adjusted EBITDA Guidance; Implements New Company Operating Structure to Enhance Focus on Rare Diseases	Q2 2018 Earnings Release 287.7 KB
07/25/18	Summary Toggle PEOPLE and Great Place to Work® Name Horizon Pharma plc to 2018 “50 Companies That Care” List	PDF Version
07/16/18	Summary Toggle Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of Additional Notices of Allowance With Claims Covering RAVICTI® (glycerol phenylbutyrate) Oral Liquid	PDF Version